Xencor (XNCR) Corporate presentation summary

Platform and financial overview

• XmAb engineering platforms enable rapid, modular drug design and clinical innovation, supported by a strong financial position with ~$542 million in cash and key partnerships as of March 2026.

• Purpose-built molecules address complex biological challenges, with rapid prototyping and optimization for defined therapeutic intent.

• Data-driven discipline and experienced development team maximize long-term value and deliver rapid clinical proof-of-concept.

Pipeline and clinical programs

• Pipeline includes next-gen T-cell engagers and novel antibodies targeting oncology (solid tumors) and autoimmune diseases, with multiple candidates in various clinical stages.

• Lead oncology programs: XmAb819 (ENPP3 x CD3) for ccRCC and XmAb541 (CLDN6 x CD3) for gynecologic and germ cell tumors; immunology programs include XmAb942 (TL1A) and XmAb412 (TL1A x IL23p19) for IBD.

• Multiple partnered programs are in pivotal or late-stage development, generating milestone and royalty revenues.

Key clinical data and milestones

• XmAb819 achieved a 25% ORR in heavily pretreated ccRCC patients, supporting progression to dose-expansion and pivotal study start in 2027.

• XmAb541 shows promising early activity in CLDN6+ tumors, with ongoing Phase 1 dose escalation.

• XmAb942 demonstrated best-in-class safety, pharmacokinetics, and immunogenicity in healthy volunteers, supporting 12-week dosing in IBD.

• XmAb412, a bispecific TL1A x IL23p19 antibody, is poised for first-in-human studies in 3Q26, with preclinical data showing high potency and favorable formulation.

• Plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) are advancing in autoimmune indications, with deep B-cell depletion and favorable safety in preclinical and early clinical studies.